[{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARAMIS Phase III Data to be Presented at ASCO 2020 Reveals Nubeqa Linked with Improved Overall Survival in Non-Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Data for NUBEQA\u00ae Plus Androgen Deprivation Therapy for Men with Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Orion Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Orion Corporation \/ Tenax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Miravo Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.0 million","newsHeadline":"Miravo Healthcare Ireland Enters into Suvexx\u00ae License and Supply Agreement with Orion Corporation for Select EU Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Naproxen Sodium","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$30.0 million","newsHeadline":"Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orion Corporation","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.14999999999999999,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARASENS Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Raises Peak Sales for Nubeqa to Exceed Three Billion Euro Amid Positive Phase III ARASENS Trial Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from an Ongoing Phase I\/II CYPIDES Trial of ODM-208 Presented at ASCO-GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fludrocortisone","moa":"CYP11A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Collaboration Partner Bayer Submits Applications in The U.S. and EU for Additional Indication of Darolutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Coated Tablet","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Collaboration Partner Bayer Submits Application for Additional Indication of Darolutamide in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Orion","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The US Food and Drug Administration (FDA) Accepts a New Supplemental Marketing Authorization Application for the Additional Indication for Darolutamide and Grants It Expedited Processing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion and the Blood Service launch Collaboration to Develop New CAR T-cell Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ CuraTeQ Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$290.0 million","newsHeadline":"Orion and MSD Announce Global Collaboration for The Development and Commercialisation Of ODM-208, An Investigational Steroid Synthesis Inhibitor for The Treatment of Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Fludrocortisone","moa":"CYP11A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ MSD","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"K-ATP channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Announces Strategic European Partnership with Orion Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Abiraterone Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for The Treatment of Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Jemincare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$16.1 million","newsHeadline":"Orion and Jemincare Enter Into an Exclusive Agreement Regarding a Non-Opioid Drug Candidate for The Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Orion","highestDevelopmentStatusID":"5","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion and Veripalvelu To Cooperate for The Development of A New CAR T Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FINLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Orion","highestDevelopmentStatusID":"1","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The FDA Approves the Use of Darolutamide in Combination with Docetaxel as An Additional Indication in The Treatment of Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion Plans to Focus Research and Product Development - In The Future on Cancer and Pain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and Bayer Are Expanding the Darolutamide Development Program in The Area of \u200b\u200bprostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Receives Approval for Additional Prostate Cancer Indication in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Receives EU Approval for Additional Indication in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Approved for Additional Prostate Cancer Indication in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and Bayer Expand Clinical Development Program for Darolutamide in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approval of Ztalmy (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Orion Corporation \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Nuvo Pharmaceuticals","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Searchlight Pharma Announces Suvexx\u00ae Launch in Europe, Along with Deal Expansion to all E.U. Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Glykos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion and Glykos Announce Research Collaboration and Licensing Agreement to Develop Next-Generation ADCs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208\/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"$410.9 million","upfrontCash":"Undisclosed","newsHeadline":"LegoChemBio Joins Hands with Orion to Become a Global Top ADC Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"LCB14","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Infusion","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,920.0 million","upfrontCash":"$290.0 million","newsHeadline":"Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Opevesostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":1.9199999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."}]
Find Clinical Drug Pipeline Developments & Deals by Orion Corporation
Details :
Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.
Details :
Under the license agreement, Tenax will be developing and commercializing the TNX-103 (levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction.
Details :
The net proceeds will be used to advance Lego's ADC pipeline including, LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2).
Details :
Under the agreement, Orion gains access to Glykos’ proprietary ADC technologies, initiating an ADC program and will be responsible for the target selection, research, development, and commercialization ...
Market Place
Reset All
